Neuroprotectant strategies that have worked in rodent models of stroke have failed to
provide protection in clinical trials. Here we show that the opposite circadian cycles in …

Occurrence of stroke cases displays a time-of-day variation in human. However, the
mechanism linking circadian rhythm to the internal response mechanisms against …

Introduction Experimental stroke studies suggest an influence of the time of day of stroke
onset on infarct progression. Whether this holds true after human stroke is unknown, but …

Stroke trials are initiated after demonstrated pharmacological protection in animal models.
NBQX protects CA1 neurons against global ischemia; however, this glutamate antagonist …

There has been a series of high-profile failures of drugs in clinical trials of acute ischaemic
stroke that were designed to meet criteria necessary for drug regulatory approval. This has …

Therapeutic interventions can only be effective when administered during their specific
“therapeutic window.” A multitude of clinical trials based on highly successful preclinical …

The concept of neuroprotective therapy for acute ischemic stroke to salvage tissue at risk
and improve functional outcome is based on sound scientific principles and extensive …

Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury
and have provided proof of principle that strategies designed to counter these mechanisms …

Acute ischaemic stroke accounts for 6.5 million deaths per year, and by 2030 will result in
the annual loss of over 200 million disability-adjusted life years globally. There have been …

Background—Neuroprotective drugs for acute stroke have appeared to work in animals,
only to fail when tested in humans. With the failure of so many clinical trials, the future of …